Frontiers in Immunology

Front Immunol. 9: 992

MicroRNA in T-Cell Development and T-Cell Mediated Acute Graft-Versus-Host Disease

Christian Koenecke¹²*, Andreas Krueger³*

¹Clinic for Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany

²Institute of Immunology, Hannover Medical School, Hannover, Germany

³Institute for Molecular Medicine, Goethe-University Frankfurt, Frankfurt am Main, Germany

Edited by: Robert Zeiser, Albert Ludwigs Universität Freiburg, Germany

Reviewed by: Benedetto Bruno, Università degli Studi di Torino, Italy; Raphael Carapito, Université de Strasbourg, France

*Correspondence: Christian Koenecke, koenecke.christian@mh-hannover.de; Andreas Krueger, andreas.krueger@kgu.de

Specialty section: This article was submitted to Alloimmunity and Transplantation, a section of the journal Frontiers in Immunology

Copyright © 2018 Koenecke and Krueger.

DOI: 10.3389/fimmu.2018.00992

Published online: 07 May 2018

Abstract

Acute graft-versus-host disease (GvHD) is still a major cause of treatment-related mortality after allogeneic stem cell transplantation. Allo-antigen recognition of donor T cells after transplantation account for the onset and persistence of this disease. MicroRNAs (miRNAs) are molecular regulators involved in numerous processes during T-cell development, homeostasis, and activation. Thus, miRNAs also contribute to pathological T-cell function during GvHD. Given their capacity of fine-tuning T-cell function, miRNAs have emerged as promising therapeutic targets to curtail acute GvHD, but simultaneously maintain T-cell-mediated graft-versus-tumor effects. Here, we review the role of key miRNAs contributing to the pathophysiology of GvHD. We focus on those miRNAs acting in T cells and for which a role in GvHD has been established in preclinical models. Finally, we provide an outlook for clinical application of this new therapeutic target for GvHD prevention and treatment.

Introduction

Acute graft-versus-host disease (GvHD) is still a major complication after allogeneic hematopoietic stem cell or bone marrow transplantation (alloSCT). Allogeneic donor T cells are the main inducers of this too often lethal disease. Donor T cells recognize and respond to allo-antigen, use chemokine receptors and integrins to home to epithelial organs, such as the liver, the intestine, or the skin and orchestrate a significant immune response, which frequently results in severe organ damage. Unspecific prophylactic and therapeutic immunosuppressive treatment is the current clinical practice to improve patients’ outcome. However, the repertory of therapeutic and preventive options is limited and, therefore, new targets to control acute GvHD are urgently needed (1).

Since T cells orchestrate this disease, they are first choice to be targeted. Only naïve donor CD4 and CD8 T cells respond to allo-antigen via the T-cell receptor (TCR) in alloSCT, whereas central and/or memory T cells are not able to induce acute GvHD (2). Depending on several signals from the microenvironment, naïve T cells respond to allo-antigens in different ways. TCR signals are usually provided by antigen-presenting cells (APCs) via MHC class I or II molecules to CD8 and CD4 T cells, respectively. Recipient and donor APCs have differential impact on GvHD-induction by donor T cells (3–9). Furthermore, additional signals via cytokines are provided by the inflamed microenvironment and lead to onset and/or acceleration of this immune response (10). Whereas the plasticity of donor CD8 T cells seem to be limited, CD4 T cells develop into different subtypes during activation. T helper (Th) subtypes, such as Th1, Th2, Th17, and regulatory T cells (Treg) have distinct functions in the course of GvHD. The main drivers of acute GvHD, at least in rodents, are Th1 and Th17 cells (11–14). The cytokine release of such subtypes ultimately leads to tissue damage, which defines the clinical outcome of the disease. However, Th2 responses with cytokines such as IL-4, IL-5, IL-9, and IL-13 contribute to acute GvHD as well (15–17). It is believed that the impact on the pathophysiology of such cytokines depends on the timing and location of cytokines released by CD4 subsets. This is especially true for the Th1 cytokine IFN-γ, which is involved in inflammatory processes but can also facilitate immunosuppressive effects (18, 19). Further Th1 type cytokines TNFα and IL-2 have been tested for the prevention and treatment of GvHD not only in experimental models but also in patients with heterogeneous results (20). Th17 cells produce cytokines such as IL-17A, IL-17F, and IL-22 under the influence of IL-23 (21). A role for Th17 and associated cytokines such as IL-17A and IL-22 during acute GvHD has been shown, however, with controversial results. In one study, IL-17A deficiency leads to disease reduction (22), whereas another study shows that absence of Th17 cells exacerbates acute GvHD (23). IL-22 has been shown to be protective during GvHD by protection of recipients’ intestinal stem cells (24). A critical role in the pathophysiology of acute GvHD is attributed to Treg cells (25–27). It has been demonstrated in preclinical animal models that thymic-derived CD4⁺CD25⁺ natural Treg cells prevent the development of severe acute GvHD while preserving graft-versus-tumor (GvT) effects (28). Clinical studies are currently underway to test the therapeutic potential of natural Treg cells as a cellular therapy (29). However, the role of induced Treg cells in the context of GvHD is less clear (30), and it is controversially discussed whether such cells are suitable for therapeutic usage. Other CD4 T cell subsets, such as T follicular helper (Tfh) cells seem to have a role in chronic GvHD, but not acute GvHD (31). Furthermore, there is some evidence that also NK cells, natural killer T cell and invariant natural killer (iNK) T cells contribute to acute GvHD pathophysiology (25).

MicroRNAs (miRNAs) Controlling T-Cell Development and Function

MicroRNAs act as post-transcriptional regulators predominantly by facilitating mRNA degradation or inhibiting translation. For most miRNAs, multiple, even hundreds, of target mRNAs have been predicted in silico, and many of those have been validated experimentally at least in some cell types (32). Conversely, mRNAs frequently contain binding sites for multiple miRNAs. Thus, miRNAs are likely to play diverse roles in controlling gene expression in different contexts dependent on both miRNA and mRNA concentration and their binding affinity. Of note, many mRNAs display a limited degree of repression through the action of an individual miRNA (33, 34). Accordingly, a major function of miRNAs might lie in controlling noise in protein expression of lowly expressed genes (35, 36) or in generating expression switches (37). In addition, it has been suggested that individual miRNAs co-target multiple mRNAs within the same pathway, thus being able to functionally control biological processes despite low levels of repression of individual mRNAs (38). In turn, some mRNAs appear to be key targets of a wide variety of miRNAs. One example constitutes the negative regulator of PI3K signaling, Pten. In addition, a pseudogene homologous to Pten has been described to act as negative regulator of miRNA-mediated regulation of Pten via competition for miRNA binding (39–41). Although the hypothesis that miRNA function is regulated via the abundance of corresponding miRNA-binding sites in competing mRNAs is compelling, quantitative analysis of miRNA copies and abundance of miRNA response elements suggested that individual competing RNAs are unlikely to significantly contribute to target derepression (42–45). Recently, Heissmeyer and colleagues demonstrated that the RNA binding Protein Roquin blocks miRNA-mediated regulation by occupying a binding site for miR-17–92 in the 3′ untranslated region (UTR) of Pten mRNA, thus adding another level of complexity to the system (46).

Despite the described complexity in miRNA–mRNA interdependence, functionally relevant regulatory one miRNA—one mRNA relationships have been demonstrated using targeted deletion of defined miRNA-binding sites in individual genes. For instance, some, but not all, functions of miR-155 in the immune system could be ascribed to its repression of Socs-1 (47). On the other hand, targeted deletion of a miR-142-binding site in Cdkn1b did not phenocopy aberrant proliferation of thymocytes observed in miR-142-deficient mice (48).

Unsurprisingly, miRNAs also play a fundamental role in T-cell development and differentiation. Thus, T-lineage specific ablation of genes essential for processing of the vast majority of miRNAs, such as Dicer, Drosha, or Dgcr8 results in aberrant T-cell development and function. Loss of virtually all miRNAs early during T-cell development results in increased levels of apoptosis of thymocytes and, concomitantly, reduced thymocyte numbers (49, 50). Deletion of Dicer at later developmental stages showed that miRNAs are critical for maintenance of peripheral T cells, most notably, the CD8 T cell compartment (51). Within the CD4 T cell compartment, loss of virtually all miRNAs resulted in a bias toward a Th1 differentiation program and against differentiation toward the Th2 and Th17 lineages (51, 52). In addition, generation of Tfh cells is dependent on miRNA (53). Furthermore, miRNAs are critical for intrathymic development as well as peripheral induction of Treg cells (54). Treg-cell specific deletion of all miRNAs resulted in fatal autoimmunity due to defective peripheral Treg-cell homeostasis (55–57).

In both T-cell development and differentiation, individual miRNAs have been extensively characterized [reviewed in Ref. (58–60)]. Here, we focus mainly on describing physiological roles of miRNAs that have been directly linked to GvHD in preclinical models or may affect critical T-cell function in the context of GvHD (Figure 1; Table 1). By comparing consequences of deletion of individual miRNAs versus deletion of the total pool of miRNAs, Dooley and colleagues identified those individual miRNAs as dominant, deletion of which helps to explain the consequences of loss of the complete miRNAome (59). In contrast, loss of individual miRNAs that does not mirror complete miRNA deficiency rather indicates functions in line with the role of miRNAs to fine-tune biological processes.

Figure 1View larger versionFigure 1. Pathophysiologically relevant microRNAs (miRNAs) in graft-versus-host disease with a functional role in T-cell development, homeostasis, and differentiation. miRNAs adjacent to arrows indicate those miRNAs that positively contribute to intrathymic development (left), proliferation and/or homeostasis (center), or differentiation of T cell subsets. miRNAs highlighted in green mirror exert major functions. Loss of these miRNAs partially mirrors depletion of all miRNAs in mice. miRNAs highlighted in red indicate miRNAs with non-dominant functions. For details, see text. Abbreviations: NKT, natural killer T cell; Treg, regulatory T cell; Tconv, conventional T cell; Th, T helper cell.

See full tableTable 1. MicroRNAs (miRNAs) acting in T cells, for which a role in graft-versus-host disease (GvHD) has been established in preclinical models.

A cluster of six related miRNAs, miR-17–92, confers competitive fitness to the earliest T-cell progenitors in the thymus and pre-thymic progenitors by regulating IL-7 receptor levels and IL-7 signaling (85). Conversely, miR-142 curtails numbers of early T-lineage progenitors, although loss of this miRNA inhibits proliferation and ultimately results in peripheral lymphopenia (48). Together, miR-17–92 and miR-142 help to explain the majority of T-lineage developmental defects observed upon early depletion of all miRNAs. Members of the miR-181 family are among the most prominently expressed miRNA species in thymocytes preceding and/or undergoing selection (75, 86). miR-181a targets a group of phosphatases, all of which act as negative regulators of TCR signaling (76). Accordingly, miR-181a sensitizes cells toward TCR signaling and may serve as a rheostat during positive selection (76,  77). Conversely, loss of miR-181a-1 and miR-181b-1 dampens TCR signaling in double-positive thymocytes (78, 79). Nevertheless, the effect of loss of miR-181a/b-1 on selection of conventional T cells (Tconv) is comparatively mild. In an HY-TCR transgenic model, loss of miR-181a/b-1 results in an increase in positively selected TCR-transgenic T cells (79). In contrast, miR-181a/b-1 is critical for development of agonist-selected iNK T cells (78, 80, 81). Although control of agonist-selected populations by miR-181 can be plausibly explained by regulation of TCR signal strength and elevated TCR expression was able to completely restore iNKT cell development, alternative mechanisms of actions, such as via regulation of Pten, cannot be fully ruled out (66, 78, 80).

Once outside the thymus miRNAs are critical for peripheral maintenance and proliferation of T cells. Thus, T cells deficient in miR-142 fail to expand after egress from the thymus and do not efficiently proliferate upon TCR triggering (48, 61). Similarly, T cells lacking miR-17–92 proliferate inefficiently after stimulation in vitro and after infection, a defect that can be partially restored by re-introduction of miR-17 and miR-92a (62, 63, 82). Despite its low levels of expression when compared to thymocytes, miR-181a has been proposed to regulate responsiveness in peripheral CD4 T cells, especially in humans. Notably, expression of miR-181a progressively declines with age, resulting high sensitivity toward TCR signals in cord blood T cells and impaired sensitivity in naive T cells from aged individuals (83, 87).

Loss of miR-29 results in a bias toward Th1 differentiation similar to that observed in pan-miRNA-deficient T cells via derepression of key transcription factors T-bet and Eomes as well as IFN-γ (62, 67). restoration of miR-29 expression in these mice can partially overcome this defect (62). miR-146a and miR-155 constitute critical miRNAs for function and homeostasis of Treg cells. Loss of miR-146a derepressed transcription factor Stat1 and, consequently, resulted in dysregulated expression of IFN-γ and accompanying immunopathology (73). The Foxp3-dependent miR-155 promotes Treg-cell homeostasis by controlling responsiveness to IL-2 signals via repression of Socs-1 (64). Combined these data place Socs-1 in a central miRNA-controlled hub of Treg cell function, because both effector signals, such as Stat1/IFN-γ as well as homeostatic signals via Stat5/IL-2 are regulated by Socs-1. Of note, disruption of the miR-155/Socs-1 axis by introducing mutations into miR-155-binding sites in the Socs1 3′UTR perturbed Treg-cell homeostasis under competitive conditions, but not at steady state, highlighting the complexity of miRNA-dependent gene regulation (47). Interestingly, although miR-17–92 contributes to regulating suppressive function via regulating production of IL-10, this cluster does not control proliferation or survival of Treg cells (88). Specific induction of miR-181a in differentiating Th17 cells can selectively sensitize these cells toward TCR-mediated signals, thus contributing to controlled memory T cell formation (89).

miRNA Function in T Cells in the Context of Acute GvHD

For a number of miRNAs, a role in the pathophysiology of acute GvHD has been described. miR-155 is important for Treg cell homeostasis and was also linked to differentiation of Tconv in autoimmune responses such as in experimental autoimmune encephalomyelitis (74, 90). miR-155 expression is upregulated in donor T cells in an experimental GvHD model and also in intestinal tissue of GvHD patients. Furthermore, donor T cells lacking miR-155 induce reduced GvHD, whereas miR-155 overexpression accelerates the course of the disease in experimental alloSCT. Consistently, blocking miR-155 by locked-nucleic-acid-modified (LNA−) anti-miR-155 oligonucelotides diminishes GvHD. In addition to alterations in T cell differentiation, impaired homing to GvHD target organs due to decreased expression of homing receptors CCR5, CXCR4, and S1P1 on effector T cells, has been proposed as the underlying molecular mechanism of blocking miR-155 (65).

Since miR-142 and miR-17–92 constitute important mediators of T cell proliferation, their contribution to GvHD pathophysiology was not unexpected. Donor T cells deficient for miR-142 show impaired cell cycle progression and simultaneously reduced proliferation, which in turn leads to reduced GvHD severity and mortality in multiple experimental alloSCT models. Mir-142 deficiency in T cells leads to upregulation of atypical E2F transcription factors E2f7 and E2f8, which are both known targets of this miRNA. Thus, targeting the interaction between miR-142 and E2F transcription factors, might serve as a potential therapeutic approach (61). T cells deficient in miR-17–92 proliferate inefficiently after stimulation in vitro and after infection (63, 82). In line with these data, miR-17–92-deficient donor T cells were unable to induce lethal acute GvHD, which could be mostly ascribed to miR-17 and miR-19b (68). Interestingly, in this model, the GvT effect was preserved, which might be due to the fact that proliferation, survival, and cytotoxic functions of CD8 T cells are at least partially maintained in the context of GvHD, when miR-17–92 is targeted. These data highlight the capacity even of broadly acting miRNAs to fine tune T cell function in a context-dependent manner.

The miR-146 family includes two members, miR-146a and miR-146b, which are both involved in acute GvHD pathophysiology. miR-146a overexpression in donor T cells reduces GvHD and in turn lack of this miRNA leads to increased GvHD severity with high levels of TNFα. In line with these experimental data, the occurrence of the SNP rs2910164 in alloSCT donors, which reduces miR-146a expression, is associated with higher incidence of severe GvHD in a patient cohort (69). One target of miR-146a in T cells is the TNF-receptor-associated factor 6 (TRAF6) (70). TRAF6 regulates transcription of TNFα via NF-κB and high levels of miR-146a reduces TNFα transcription in donor T cells and thereby reduces GvHD. TRAF6 is also a target of miR-146b and antagomir-mediated knockdown of miR-146b leads to enhanced TRAF6 expression. Increased TRAF6, in turn, activates NF-κB and leads to enhanced survival, proliferation, and suppressive activity of natural Treg cells. Hence, miR-146b antagomir-treated human Treg cells decrease mortality in a xenogenic GvHD-model and might, therefore, improve the adoptive Treg cell therapy (91). The opposing functions of the closely related miR-146a and miR-146b shed light on the complexity of miRNA-based intervention to treat GvHD.

Indoleamine-2,3-dioxygenase (IDO) is a critical enzyme in providing essential amino acids for T cell proliferation and exerts immunosuppressive effects. Increased levels of IDO levels prevent acute GvHD (72). IDO is directly targeted by miR-153-3p and miR-153-3p. Antagomir for miR-153-3p and miR-153-3p led to higher IDO expression in experimental GvHD and delayed the course of disease (84).

miR-181a acts as a rheostat for T cell sensitivity to antigen by downregulation of several phosphatases downstream of the TCR (76). Primary T cells overexpressing miR-181a failed to induce experimental GvHD, whereas, conversely, donor T cells lacking miR-181a/b-1 accelerated acute GvHD in the same model (92). Overexpression of miR-181a resulted in decreased T cell survival, most likely because of reduced expression of anti-apoptotic BCL-2 protein expression. Repression of BCL-2 protein in this context likely results from a combination of it being a direct target of miR-181a as well as a consequence of apoptosis regulation dependent on TCR signal strength. This study points toward BCL-2 inhibition as a novel therapeutic strategy in prevention of allo-reactivity and highlights miRNAs as titrable therapeutic targets in order to prevent GvHD while preserving GvT effects.

Future Directions

Understanding the role of miRNAs in physiological T cell function and in the context of disease has the potential to open up new avenues for therapy. Most of this knowledge is derived from the analysis of rodent models and is only beginning to be complemented by studies in human primary T cells (93). To a large extent, miRNAs and their mRNA target sites are evolutionary conserved. However, some notable exceptions have been described. Thus, miR-125b controls human T cell differentiation via a number of mRNA targets lacking corresponding miR-125b binding sites in mouse, including the genes encoding IFN-γ and IL-10RA (93). In terms of therapeutic delivery, alloSCT has the distinct advantage that cells might already be manipulated prior to transplantation ex vivo. Recently, methods for efficient CRISPR/Cas9-mediated genome engineering of primary human T cells have been reported (94). In addition, highly potent chemically modified miRNA analogs or antagonists are beginning to emerge that can be directly delivered in vivo (95, 96), some of which have already been employed experimentally in rodent models of GvHD (65, 69). In order to prevent off-target effects in case of systemic delivery such miRNAs can be further modified to generate compounds that can be selectively activated through light in typical GvHD target organs, such as skin and gut (97).

Our knowledge of miRNA action is far from complete and a number of miRNAs with a role in T cell function, for instance, miR-148a, miR-182, and miR-326, may ultimately also play a role in GvHD (98–100). Similarly, a number of miRNAs have been identified as putative biomarkers for GvHD, such as miR-194, but a functional role in pathogenesis remains to be established (101). Finally, miRNAs also play a role in non-T cells during GvHD. For instance, miR-100 has been reported to limit neovascularization in the intestine and miR-155, which functions as a key regulator of Treg cells as well as Tconv, negatively impacts upon dendritic cell function during GvHD (102, 103).

Conclusion

MicroRNAs play critical role in many biological processes including T-cell development and differentiation. Given that GvHD is a predominantly T-cell driven disease, miRNAs have emerged as attractive therapeutic targets for ex vivo and potentially even in vivo modulation. A better understanding of miRNAs controlling physiologic T-cell function has resulted in efficient translation of manipulation of miRNAs in preclinical models of GvHD. However, despite the generally broad interspecies conservation of miRNAs, translation into clinical treatment of GvHD remains a challenge.

Author Contributions

All authors listed have made a substantial, direct, and intellectual contribution to the work and approved it for publication.

Conflict of Interest Statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Footnotes

Funding. This work was supported by Deutsche Forschungsgemeinschaft (www.dfg.de): SFB738/A8 and SFB900/B8 to CK and SFB902/B15 and KR2320/5-1 to AK.

Articles from Frontiers in Immunology are provided here courtesy of Frontiers Media SA

PMC Copyright Notice

The articles available from the PMC site are protected by copyright, even though access is free. Copyright is held by the respective authors or publishers who provide these articles to PMC. Users of PMC are responsible for complying with the terms and conditions defined by the copyright holder.

Users should assume that standard copyright protection applies to articles in PMC, unless an article contains an explicit license statement that gives a user additional reuse or redistribution rights. PMC does not allow automated/bulk downloading of articles that have standard copyright protection.

See the copyright notice on the PMC site, https://www.ncbi.nlm.nih.gov/pmc/about/copyright/, for further details and specific exceptions.

References

R ZeiserBR Blazar Acute graft-versus-host disease – biologic process, prevention, and therapy. N Engl J Med (2017) 377(22):2167–79.10.1056/NEJMra160933729171820

H ZhengC Matte-MartoneH LiBE AndersonS VenketesanH Sheng Tan Effector memory CD4+ T cells mediate graft-versus-leukemia without inducing graft-versus-host disease. Blood (2008) 111(4):2476–84.10.1182/blood-2007-08-10967818045967

CC MatteJ LiuJ CormierBE AndersonI AthanasiadisD Jain Donor APCs are required for maximal GVHD but not for GVL. Nat Med (2004) 10(9):987–92.10.1038/nm108915286785

WD ShlomchikMS CouzensCB TangJ McNiffME RobertJ Liu Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science (1999) 285(5426):412–5.10.1126/science.285.5426.41210411505

BE AndersonJM McNiffD JainBR BlazarWD ShlomchikMJ Shlomchik. Distinct roles for donor- and host-derived antigen-presenting cells and costimulatory molecules in murine chronic graft-versus-host disease: requirements depend on target organ. Blood (2005) 105(5):2227–34.10.1182/blood-2004-08-303215522961

UA DuffnerY MaedaKR CookeP ReddyR OrdemannC Liu Host dendritic cells alone are sufficient to initiate acute graft-versus-host disease. J Immunol (2004) 172(12):7393–8.10.4049/jimmunol.172.12.739315187116

KA MarkeyT BanovicRD KunsSD OlverAL DonNC Raffelt Conventional dendritic cells are the critical donor APC presenting alloantigen after experimental bone marrow transplantation. Blood (2009) 113(22):5644–9.10.1182/blood-2008-12-19183319336758

T TeshimaR OrdemannP ReddyS GaginC LiuKR Cooke Acute graft-versus-host disease does not require alloantigen expression on host epithelium. Nat Med (2002) 8(6):575–81.10.1038/nm0902-1039a12042807

M KoyamaRD KunsSD OlverNC RaffeltYA WilsonAL Don Recipient nonhematopoietic antigen-presenting cells are sufficient to induce lethal acute graft-versus-host disease. Nat Med (2011) 18(1):135–42.10.1038/nm.259722127134

R ChakravertyD CoteJ BuchliP CotterR HsuG Zhao An inflammatory checkpoint regulates recruitment of graft-versus-host reactive T cells to peripheral tissues. J Exp Med (2006) 203(8):2021–31.10.1084/jem.2006037616880259

MM ImanguliWD SwaimSC LeagueRE GressSZ PavleticFT Hakim. Increased T-bet+ cytotoxic effectors and type I interferon-mediated processes in chronic graft-versus-host disease of the oral mucosa. Blood (2009) 113(15):3620–30.10.1182/blood-2008-07-16835119168793

WJ MurphyLA WelniakDD TaubRH WiltroutPA TaylorDA Vallera Differential effects of the absence of interferon-gamma and IL-4 in acute graft-versus-host disease after allogeneic bone marrow transplantation in mice. J Clin Invest (1998) 102(9):1742–8.10.1172/JCI39069802888

B NikolicS LeeRT BronsonMJ GrusbyM Sykes. Th1 and Th2 mediate acute graft-versus-host disease, each with distinct end-organ targets. J Clin Invest (2000) 105(9):1289–98.10.1172/JCI789410792004

P RatajczakA JaninR Peffault de LatourC LeboeufA DesveauxK Keyvanfar Th17/Treg ratio in human graft-versus-host disease. Blood (2010) 116(7):1165–71.10.1182/blood-2009-12-25581020484086

DH FowlerRE Gress. Th2 and Tc2 cells in the regulation of GVHD, GVL, and graft rejection: considerations for the allogeneic transplantation therapy of leukemia and lymphoma. Leuk Lymphoma (2000) 38(3–4):221–34.10.3109/1042819000908701410830730

DB Leveson-GowerJA OlsonEI SegaRH LuongJ BakerR Zeiser Low doses of natural killer T cells provide protection from acute graft-versus-host disease via an IL-4-dependent mechanism. Blood (2011) 117(11):3220–9.10.1182/blood-2010-08-30300821258007

I TawaraY MaedaY SunKP LowlerC LiuT Toubai Combined Th2 cytokine deficiency in donor T cells aggravates experimental acute graft-vs-host disease. Exp Hematol (2008) 36(8):988–96.10.1016/j.exphem.2008.02.01018410989

Y LuEK Waller. Dichotomous role of interferon-gamma in allogeneic bone marrow transplant. Biol Blood Marrow Transplant (2009) 15(11):1347–53.10.1016/j.bbmt.2009.07.01519822293

C KoeneckeCW LeeK ThammL FohseM SchafferusHW Mittrucker IFN-gamma production by allogeneic Foxp3+ regulatory T cells is essential for preventing experimental graft-versus-host disease. J Immunol (2012) 189(6):2890–6.10.4049/jimmunol.120041322869903

AM AlousiDJ WeisdorfBR LoganJ Bolanos-MeadeS CarterN Difronzo Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: a randomized phase 2 trial from the Blood and Marrow Transplant Clinical Trials Network. Blood (2009) 114(3):511–7.10.1182/blood-2009-03-21229019443659

SL GaffenR JainAV GargDJ Cua. The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing. Nat Rev Immunol (2014) 14(9):585–600.10.1038/nri370725145755

LW KappelGL GoldbergCG KingDY SuhOM SmithC Ligh IL-17 contributes to CD4-mediated graft-versus-host disease. Blood (2009) 113(4):945–52.10.1182/blood-2008-08-17215518931341

T YiD ZhaoCL LinC ZhangY ChenI Todorov Absence of donor Th17 leads to augmented Th1 differentiation and exacerbated acute graft-versus-host disease. Blood (2008) 112(5):2101–10.10.1182/blood-2007-12-12698718596226

AM HanashLW KappelNL YimRA NejatGL GoldbergOM Smith Abrogation of donor T-cell IL-21 signaling leads to tissue-specific modulation of immunity and separation of GVHD from GVL. Blood (2011) 118(2):446–55.10.1182/blood-2010-07-29478521596854

R ZeiserG SocieBR Blazar. Pathogenesis of acute graft-versus-host disease: from intestinal microbiota alterations to donor T cell activation. Br J Haematol (2016) 175(2):191–207.10.1111/bjh.1429527619472

I PrinzC Koenecke Therapeutic potential of induced and natural FoxP3(+) regulatory T cells for the treatment of graft-versus-host disease. Arch Immunol Ther Exp (Warsz) (2012) 60(3):183–90.10.1007/s00005-012-0172-322476537

KL HippenM LoschiJ NichollsKPA MacDonaldBR Blazar. Effects of microRNA on regulatory T cells and implications for adoptive cellular therapy to ameliorate graft-versus-host disease. Front Immunol (2018) 9:57.10.3389/fimmu.2018.0005729445371

M EdingerP HoffmannJ ErmannK DragoCG FathmanS Strober CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat Med (2003) 9(9):1144–50.10.1038/nm91512925844

CG BrunsteinJS MillerDH McKennaKL HippenTE DeForD Sumstad Umbilical cord blood-derived T regulatory cells to prevent GVHD: kinetics, toxicity profile, and clinical effect. Blood (2016) 127(8):1044–51.10.1182/blood-2015-06-65366726563133

C KoeneckeN CzelothA BubkeS SchmitzA KissenpfennigB Malissen Alloantigen-specific de novo-induced Foxp3+ Treg revert in vivo and do not protect from experimental GVHD. Eur J Immunol (2009) 39(11):3091–6.10.1002/eji.20093943219750478

R FlynnJ DuRG VeenstraDK ReichenbachA Panoskaltsis-MortariPA Taylor Increased T follicular helper cells and germinal center B cells are required for cGVHD and bronchiolitis obliterans. Blood (2014) 123(25):3988–98.10.1182/blood-2014-03-56223124820310

CH ChouS ShresthaCD YangNW ChangYL LinKW Liao miRTarBase update 2018: a resource for experimentally validated microRNA-target interactions. Nucleic Acids Res (2018) 46(D1):D296–302.10.1093/nar/gkx106729126174

M SelbachB SchwanhausserN ThierfelderZ FangR KhaninN Rajewsky. Widespread changes in protein synthesis induced by microRNAs. Nature (2008) 455(7209):58–63.10.1038/nature0722818668040

H GuoNT IngoliaJS WeissmanDP Bartel. Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature (2010) 466(7308):835–40.10.1038/nature0926720703300

JM SchmiedelSL KlemmY ZhengA SahayN BluthgenDS Marks Gene expression. MicroRNA control of protein expression noise. Science (2015) 348(6230):128–32.10.1126/science.aaa173825838385

H HerranzSM Cohen. MicroRNAs and gene regulatory networks: managing the impact of noise in biological systems. Genes Dev (2010) 24(13):1339–44.10.1101/gad.193701020595229

S MukherjiMS EbertGX ZhengJS TsangPA SharpA van Oudenaarden. MicroRNAs can generate thresholds in target gene expression. Nat Genet (2011) 43(9):854–9.10.1038/ng.90521857679

JS TsangMS EbertA van Oudenaarden. Genome-wide dissection of microRNA functions and cotargeting networks using gene set signatures. Mol Cell (2010) 38(1):140–53.10.1016/j.molcel.2010.03.00720385095

L PolisenoL SalmenaJ ZhangB CarverWJ HavemanPP Pandolfi. A coding-independent function of gene and pseudogene mRNAs regulates tumour biology. Nature (2010) 465(7301):1033–8.10.1038/nature0914420577206

Y TayL KatsL SalmenaD WeissSM TanU Ala Coding-independent regulation of the tumor suppressor PTEN by competing endogenous mRNAs. Cell (2011) 147(2):344–57.10.1016/j.cell.2011.09.02922000013

L SalmenaL PolisenoY TayL KatsPP Pandolfi. A ceRNA hypothesis: the Rosetta Stone of a hidden RNA language? Cell (2011) 146(3):353–8.10.1016/j.cell.2011.07.01421802130

H Seitz. Redefining microRNA targets. Curr Biol (2009) 19(10):870–3.10.1016/j.cub.2009.03.05919375315

MS EbertPA Sharp. Roles for microRNAs in conferring robustness to biological processes. Cell (2012) 149(3):515–24.10.1016/j.cell.2012.04.00522541426

R DenzlerSE McGearyAC TitleV AgarwalDP BartelM Stoffel. Impact of microRNA levels, target-site complementarity, and cooperativity on competing endogenous RNA-regulated gene expression. Mol Cell (2016) 64(3):565–79.10.1016/j.molcel.2016.09.02727871486

M JensN Rajewsky. Competition between target sites of regulators shapes post-transcriptional gene regulation. Nat Rev Genet (2015) 16(2):113–26.10.1038/nrg385325488579

K EssigD HuJC GuimaraesD AlteraugeS EdelmannT Raj Roquin suppresses the PI3K-mTOR signaling pathway to inhibit T helper cell differentiation and conversion of Treg to Tfr cells. Immunity (2017) 47(6):1067–82 e12.10.1016/j.immuni.2017.11.00829246441

LF LuG GasteigerIS YuA ChaudhryJP HsinY Lu A single miRNA-mRNA interaction affects the immune response in a context- and cell-type-specific manner. Immunity (2015) 43(1):52–64.10.1016/j.immuni.2015.04.02226163372

A MildnerE ChapnikD VarolT AychekN LamplN Rivkin MicroRNA-142 controls thymocyte proliferation. Eur J Immunol (2017) 47(7):1142–52.10.1002/eji.20174698728471480

BS CobbTB NesterovaE ThompsonA HertweckE O’ConnorJ Godwin T cell lineage choice and differentiation in the absence of the RNase III enzyme Dicer. J Exp Med (2005) 201(9):1367–73.10.1084/jem.2005057215867090

MM ChongG ZhangS CheloufiTA NeubertGJ HannonDR Littman. Canonical and alternate functions of the microRNA biogenesis machinery. Genes Dev (2010) 24(17):1951–60.10.1101/gad.195331020713509

SA MuljoKM AnselC KanellopoulouDM LivingstonA RaoK Rajewsky. Aberrant T cell differentiation in the absence of Dicer. J Exp Med (2005) 202(2):261–9.10.1084/jem.2005067816009718

K IchiyamaA Gonzalez-MartinBS KimHY JinW JinW Xu The microRNA-183-96-182 cluster promotes T helper 17 cell pathogenicity by negatively regulating transcription factor Foxo1 expression. Immunity (2016) 44(6):1284–98.10.1016/j.immuni.2016.05.01527332731

D BaumjohannR KageyamaJM ClinganMM MorarS PatelD de Kouchkovsky The microRNA cluster miR-17 approximately 92 promotes TFH cell differentiation and represses subset-inappropriate gene expression. Nat Immunol (2013) 14(8):840–8.10.1038/ni.264223812098

BS CobbA HertweckJ SmithE O’ConnorD GrafT Cook A role for Dicer in immune regulation. J Exp Med (2006) 203(11):2519–27.10.1084/jem.2006169217060477

A ListonLF LuD O’CarrollA TarakhovskyAY Rudensky. Dicer-dependent microRNA pathway safeguards regulatory T cell function. J Exp Med (2008) 205(9):1993–2004.10.1084/jem.2008106218725526

MM ChongJP RasmussenAY RudenskyDR Littman. The RNAseIII enzyme Drosha is critical in T cells for preventing lethal inflammatory disease. J Exp Med (2008) 205(9):2005–17.10.1084/jem.2008121918725527

X ZhouLT JekerBT FifeS ZhuMS AndersonMT McManus Selective miRNA disruption in T reg cells leads to uncontrolled autoimmunity. J Exp Med (2008) 205(9):1983–91.10.1084/jem.2008070718725525

D BaumjohannKM Ansel. MicroRNA-mediated regulation of T helper cell differentiation and plasticity. Nat Rev Immunol (2013) 13(9):666–78.10.1038/nri349423907446

J DooleyMA LintermanA Liston. MicroRNA regulation of T-cell development. Immunol Rev (2013) 253(1):53–64.10.1111/imr.1204923550638

S Monticelli. MicroRNAs in T helper cell differentiation and plasticity. Semin Immunol (2013) 25(4):291–8.10.1016/j.smim.2013.10.01524216176

Y SunK Oravecz-WilsonN MathewsonY WangR McEachinC Liu Mature T cell responses are controlled by microRNA-142. J Clin Invest (2015) 125(7):2825–40.10.1172/JCI7875326098216

DF SteinerMF ThomasJK HuZ YangJE BabiarzCD Allen MicroRNA-29 regulates T-box transcription factors and interferon-gamma production in helper T cells. Immunity (2011) 35(2):169–81.10.1016/j.immuni.2011.07.00921820330

T WuA WielandJ LeeJS HaleJH HanX Xu Cutting edge: miR-17-92 is required for both CD4 Th1 and T follicular helper cell responses during viral infection. J Immunol (2015) 195(6):2515–9.10.4049/jimmunol.150031726276869

LF LuTH ThaiDP CaladoA ChaudhryM KuboK Tanaka Foxp3-dependent microRNA155 confers competitive fitness to regulatory T cells by targeting SOCS1 protein. Immunity (2009) 30(1):80–91.10.1016/j.immuni.2008.11.01019144316

P RanganathanCE HeaphyS CostineanN StaufferC NaM Hamadani Regulation of acute graft-versus-host disease by microRNA-155. Blood (2012) 119(20):4786–97.10.1182/blood-2011-10-38752222408260

J BlumeS Zur LageK WitzlauH GeorgievS WeissM Lyszkiewicz Overexpression of Valpha14Jalpha18 TCR promotes development of iNKT cells in the absence of miR-181a/b-1. Immunol Cell Biol (2016) 94(8):741–6.10.1038/icb.2016.4027089939

F MaS XuX LiuQ ZhangX XuM Liu The microRNA miR-29 controls innate and adaptive immune responses to intracellular bacterial infection by targeting interferon-gamma. Nat Immunol (2011) 12(9):861–9.10.1038/ni.207321785411

Y WuJ HeinrichsD BastianJ FuH NguyenS Schutt MicroRNA-17-92 controls T-cell responses in graft-versus-host disease and leukemia relapse in mice. Blood (2015) 126(11):1314–23.10.1182/blood-2015-02-62735626138686

N StickelG PrinzD PfeiferP HasselblattA Schmitt-GraeffM Follo miR-146a regulates the TRAF6/TNF-axis in donor T cells during GVHD. Blood (2014) 124(16):2586–95.10.1182/blood-2014-04-56904625205119

L YangMP BoldinY YuCS LiuCK EaP Ramakrishnan miR-146a controls the resolution of T cell responses in mice. J Exp Med (2012) 209(9):1655–70.10.1084/jem.2011221822891274

Y ZhangW LiuY ChenJ LiuK WuL Su A cellular microRNA facilitates regulatory T lymphocyte development by targeting the FOXP3 promoter TATA-box motif. J Immunol (2018) 200(3):1053–63.10.4049/jimmunol.170019629282311

LK JaspersonC BucherA Panoskaltsis-MortariAL MellorDH MunnBR Blazar. Inducing the tryptophan catabolic pathway, indoleamine 2,3-dioxygenase (IDO), for suppression of graft-versus-host disease (GVHD) lethality. Blood (2009) 114(24):5062–70.10.1182/blood-2009-06-22758719828695

LF LuMP BoldinA ChaudhryLL LinKD TaganovT Hanada Function of miR-146a in controlling Treg cell-mediated regulation of Th1 responses. Cell (2010) 142(6):914–29.10.1016/j.cell.2010.08.01220850013

RM O’ConnellD KahnWS GibsonJL RoundRL ScholzAA Chaudhuri MicroRNA-155 promotes autoimmune inflammation by enhancing inflammatory T cell development. Immunity (2010) 33(4):607–19.10.1016/j.immuni.2010.09.00920888269

S KuchenW ReschA YamaneN KuoZ LiT Chakraborty Regulation of microRNA expression and abundance during lymphopoiesis. Immunity (2010) 32(6):828–39.10.1016/j.immuni.2010.05.00920605486

QJ LiJ ChauPJ EbertG SylvesterH MinG Liu miR-181a is an intrinsic modulator of T cell sensitivity and selection. Cell (2007) 129(1):147–61.10.1016/j.cell.2007.03.00817382377

PJ EbertS JiangJ XieQJ LiMM Davis. An endogenous positively selecting peptide enhances mature T cell responses and becomes an autoantigen in the absence of microRNA miR-181a. Nat Immunol (2009) 10(11):1162–9.10.1038/ni.179719801983

N ZietaraM LyszkiewiczK WitzlauR NaumannR HurwitzJ Langemeier Critical role for miR-181a/b-1 in agonist selection of invariant natural killer T cells. Proc Natl Acad Sci U S A (2013) 110(18):7407–12.10.1073/pnas.122198411023589855

SA SchaffertC LohS WangCP ArnoldRC AxtellEW Newell mir-181a-1/b-1 modulates tolerance through opposing activities in selection and peripheral T cell function. J Immunol (2015) 195(4):1470–9.10.4049/jimmunol.140158726163591

J Henao-MejiaA WilliamsLA GoffM StaronP Licona-LimonSM Kaech The microRNA miR-181 is a critical cellular metabolic rheostat essential for NKT cell ontogenesis and lymphocyte development and homeostasis. Immunity (2013) 38(5):984–97.10.1016/j.immuni.2013.02.02123623381

I SandrockN ZietaraM LyszkiewiczL OberdorferK WitzlauA Krueger MicroRNA-181a/b-1 is not required for innate gammadelta NKT effector cell development. PLoS One (2015) 10(12):e014501010.1371/journal.pone.014501026673421

T WuA WielandK ArakiCW DavisL YeJS Hale Temporal expression of microRNA cluster miR-17-92 regulates effector and memory CD8+ T-cell differentiation. Proc Natl Acad Sci U S A (2012) 109(25):9965–70.10.1073/pnas.120732710922665768

AC PalinV RamachandranS AcharyaDB Lewis. Human neonatal naive CD4+ T cells have enhanced activation-dependent signaling regulated by the microRNA miR-181a. J Immunol (2013) 190(6):2682–91.10.4049/jimmunol.120253423408835

XS ZhaoYN WangM LvY KongHX LuoXY Ye miR-153-3p, a new bio-target, is involved in the pathogenesis of acute graft-versus-host disease via inhibition of indoleamine-2,3-dioxygenase. Oncotarget (2016) 7(30):48321–34.10.18632/oncotarget.1022027340781

M RegelinJ BlumeJ PommerenckeR VakilzadehK WitzlauM Lyszkiewicz Responsiveness of developing T cells to IL-7 signals is sustained by miR-17 approximately 92. J Immunol (2015) 195(10):4832–40.10.4049/jimmunol.140224826475928

FF KiriginK LindstedtM SellarsM CiofaniSL LowL Jones Dynamic microRNA gene transcription and processing during T cell development. J Immunol (2012) 188(7):3257–67.10.4049/jimmunol.110317522379031

G LiM YuWW LeeM TsangE KrishnanCM Weyand Decline in miR-181a expression with age impairs T cell receptor sensitivity by increasing DUSP6 activity. Nat Med (2012) 18(10):1518–24.10.1038/nm.296323023500

D de KouchkovskyJH EsenstenWL RosenthalMM MorarJA BluestoneLT Jeker. microRNA-17-92 regulates IL-10 production by regulatory T cells and control of experimental autoimmune encephalomyelitis. J Immunol (2013) 191(4):1594–605.10.4049/jimmunol.120356723858035

F MeleC BassoC LeoniD AschenbrennerS BecattiniD Latorre ERK phosphorylation and miR-181a expression modulate activation of human memory TH17 cells. Nat Commun (2015) 6:6431.10.1038/ncomms743125775432

G MurugaiyanV BeynonA MittalN JollerHL Weiner. Silencing microRNA-155 ameliorates experimental autoimmune encephalomyelitis. J Immunol (2011) 187(5):2213–21.10.4049/jimmunol.100395221788439

Y LuKL HippenAL LemireJ GuW WangX Ni miR-146b antagomir-treated human Tregs acquire increased GVHD inhibitory potency. Blood (2016) 128(10):1424–35.10.1182/blood-2016-05-71453527485827

CW LeeK WohlanI DallmannR ForsterA GanserA Krueger miR-181a expression in donor T cells modulates graft-versus-host disease after allogeneic bone marrow transplantation. J Immunol (2016) 196(9):3927–34.10.4049/jimmunol.150215227009493

RL RossiG RossettiL WenandyS CurtiA RipamontiRJ Bonnal Distinct microRNA signatures in human lymphocyte subsets and enforcement of the naive state in CD4+ T cells by the microRNA miR-125b. Nat Immunol (2011) 12(8):796–803.10.1038/ni.205721706005

A SekiS Rutz. Optimized RNP transfection for highly efficient CRISPR/Cas9-mediated gene knockout in primary T cells. J Exp Med (2018) 215(3):985–97.10.1084/jem.2017162629436394

P MaschmeyerG PetkauF SiracusaJ ZimmermannF ZugelAA Kuhl Selective targeting of pro-inflammatory Th1 cells by microRNA-148a-specific antagomirs in vivo. J Autoimmun (2017) 89:41–52.10.1016/j.jaut.2017.11.00529183643

J KrutzfeldtN RajewskyR BraichKG RajeevT TuschlM Manoharan Silencing of microRNAs in vivo with ’antagomirs’. Nature (2005) 438(7068):685–9.10.1038/nature0430316258535

T LucasF SchaferP MullerSA EmingA HeckelS Dimmeler. Light-inducible antimiR-92a as a therapeutic strategy to promote skin repair in healing-impaired diabetic mice. Nat Commun (2017) 8:15162.10.1038/ncomms1516228462946

C HaftmannAB StittrichJ ZimmermannZ FangK HradilkovaM Bardua miR-148a is upregulated by Twist1 and T-bet and promotes Th1-cell survival by regulating the proapoptotic gene Bim. Eur J Immunol (2015) 45(4):1192–205.10.1002/eji.20144463325486906

AB StittrichC HaftmannE SgouroudisAA KuhlAN HegazyI Panse The microRNA miR-182 is induced by IL-2 and promotes clonal expansion of activated helper T lymphocytes. Nat Immunol (2010) 11(11):1057–62.10.1038/ni.194520935646

C DuC LiuJ KangG ZhaoZ YeS Huang MicroRNA miR-326 regulates TH-17 differentiation and is associated with the pathogenesis of multiple sclerosis. Nat Immunol (2009) 10(12):1252–9.10.1038/ni.179819838199

S GimondiM DugoA VendraminA BermemaG BianconA Cavane Circulating miRNA panel for prediction of acute graft-versus-host disease in lymphoma patients undergoing matched unrelated hematopoietic stem cell transplantation. Exp Hematol (2016) 44(7):624–34 e1.10.1016/j.exphem.2016.03.00527013207

F LeonhardtS GrundmannM BeheF BluhmRA DumontF Braun Inflammatory neovascularization during graft-versus-host disease is regulated by alphav integrin and miR-100. Blood (2013) 121(17):3307–18.10.1182/blood-2012-07-44266523327924

S ChenBA SmithJ IypeA PrestipinoD PfeiferS Grundmann MicroRNA-155-deficient dendritic cells cause less severe GVHD through reduced migration and defective inflammasome activation. Blood (2015) 126(1):103–12.10.1182/blood-2014-12-61725825972159

[Back]

Figure 1.

Pathophysiologically relevant microRNAs (miRNAs) in graft-versus-host disease with a functional role in T-cell development, homeostasis, and differentiation. miRNAs adjacent to arrows indicate those miRNAs that positively contribute to intrathymic development (left), proliferation and/or homeostasis (center), or differentiation of T cell subsets. miRNAs highlighted in green mirror exert major functions. Loss of these miRNAs partially mirrors depletion of all miRNAs in mice. miRNAs highlighted in red indicate miRNAs with non-dominant functions. For details, see text. Abbreviations: NKT, natural killer T cell; Treg, regulatory T cell; Tconv, conventional T cell; Th, T helper cell.

[Back]

[Back]

Table 1.

MicroRNAs (miRNAs) acting in T cells, for which a role in graft-versus-host disease (GvHD) has been established in preclinical models.

miRNA
Physiologic function
Role in GvHD
Reference

miR-17–92

Promotes early T-cell development

Promotes activation-dependent T-cell proliferation

Regulates regulatory T cell (Treg) cell suppressive function

Pathogenic
(60–65)

miR-142

Curtails T-cell progenitor numbers

Promotes T-cell proliferation

Pathogenic
(47, 66)

miR-146a

Promotes Treg-cell homeostasis

Beneficial
(67–69)

miR-146b

n.d.

Pathogenic
(70)

miR-153-3p

Prevents immunosuppression through indoleamine-2,3-dioxygenase

Pathogenic
(71, 72)

miR-155

Promotes Treg cell homeostasis

Pathogenic
(73, 74)

miR-181a

Rheostat for T-cell receptor signaling

Promotes development of invariant natural killer T cells

Beneficial
(75–84)

[Back]